Acquisition by John Neis of 25000 shares of Cellectar Biosciences subject to Rule 16b-3

CLRB Stock  USD 1.46  0.06  3.95%   
About 61% of Cellectar Biosciences' investor base is looking to short. The analysis of the overall investor sentiment regarding Cellectar Biosciences suggests that many traders are alarmed. The current market sentiment, together with Cellectar Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Cellectar Biosciences stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Cellectar Biosciences Inc director. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Cellectar insider trading alert for grant of stock option right to buy by John Neis, the corporate stakeholder, on 19th of February 2024. This event was filed by Cellectar Biosciences Inc with SEC on 2023-06-28. Statement of changes in beneficial ownership - SEC Form 4

Cellectar Biosciences Fundamental Analysis

We analyze Cellectar Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cellectar Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cellectar Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Cash Per Share

Cash Per Share Comparative Analysis

Cellectar Biosciences is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Cellectar Biosciences Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cellectar Biosciences stock to make a market-neutral strategy. Peer analysis of Cellectar Biosciences could also be used in its relative valuation, which is a method of valuing Cellectar Biosciences by comparing valuation metrics with similar companies.

Peers

Cellectar Biosciences Related Equities

TENXTenax Therapeutics   5.59   
0%
35.0%
MNPRMonopar Therapeutics   5.27   
0%
33.0%
BNTCBenitec Biopharma   2.46   
0%
15.0%
LBPHLongboard Pharmaceuticals   0.00   
0%
0%
LUMOLumos Pharma   0.46   
2.0%
0%
BOLTBolt Biotherapeutics   1.56   
9.0%
0%
PULMPulmatrix   1.89   
11.0%
0%
NXTCNextCure   2.59   
16.0%
0%
BPTHBio Path   4.05   
25.0%
0%
ALRNAileron Therapeutics   8.77   
55.0%
0%
CAPRCapricor Therapeutics   15.94   
100.0%
0%

Complementary Tools for Cellectar Stock analysis

When running Cellectar Biosciences' price analysis, check to measure Cellectar Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectar Biosciences is operating at the current time. Most of Cellectar Biosciences' value examination focuses on studying past and present price action to predict the probability of Cellectar Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectar Biosciences' price. Additionally, you may evaluate how the addition of Cellectar Biosciences to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Equity Valuation
Check real value of public entities based on technical and fundamental data
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities